MARA Rating’s Patient Population score (A++–C) predicts HTA approval & reimbursement success. Learn how robust subgroup analysis and real-world evidence drive payer confidence.

Too often, M&A teams under-weight market-access risk—patient population evidence can make or break your HTA submission. A mere 0.2-point uptick in our Patient Population score (3.1 vs. 2.9) correlates with significantly higher HTA approval rates and fewer payer-mandated caveats.

Data-Driven Insight

• HTA Success Differential – Since 2020, assets averaging a 3.1 score passed health-technology assessments more reliably than those at 2.9, which triggered subgroup concerns and coverage restrictions.
• Real-World Evidence (RWE) – Demonstrating that trial participants mirror real-world demographics is pivotal for securing broad reimbursement and reducing post-launch data commitments.

Our Independent Scoring Framework

We translate population criteria from NICE (UK), G-BA/IQWiG (Germany) and ICER (US) into a clear A++→C rating—now applied to 350+ assets. This standardized, SEO-rich MARA Rating quantifies:

1. Representativeness – Alignment of inclusion/exclusion criteria with target age ranges, disease severity and comorbidity profiles.
2. Subgroup Analysis – Prespecified outcomes for elderly, genetic variants and other key cohorts.
3. Generalizability – Confidence that trial outcomes extend across diverse healthcare environments.
4. Special Populations – Adequacy of pediatric, geriatric and high-need subgroup data.

Strategic Recommendations

• Market Access Leaders: Perform epidemiology mapping by region; proactively address under-represented subgroups.
• Venture Investors & Acquirers: Prioritize assets with robust subgroup evidence to de-risk global roll-out.
• Clinical Development Teams: Embed broad, scientifically justified eligibility and prespecify subgroup endpoints in protocols.

Your Next Step

Our anonymized distribution of 350+ assets pinpoints exactly where your patient population evidence excels—and where it needs reinforcement. Do you know how your product measures up?

Explore 350+ independent assessments in our online catalogue: https://mararating.com/mara-ratings-list

Follow MARA Rating for more independent HTA insights: linkedin.com/company/mara-rating-company

#MarketAccessRiskAssessment #HTAApproval #RealWorldEvidence #PatientPopulation #SubgroupAnalysis #MARARating #ReimbursementStrategy